Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 19, 2009 - Issue 10
Submit an article Journal homepage
63
Views
1
CrossRef citations to date
0
Altmetric
Patent Evaluations

Diazepane–acetamide derivatives as selective 11β-hydroxysteroid dehydrogenase type 1 inhibitors

Alex Odermatt University of Basel, Division of Molecular and Systems Toxicology, Department of Pharmaceutical Sciences, Klingelbergstrasse 50, 4056 Basel, Switzerland +41 61 267 1530; +41 61 267 1515; [email protected]
, PhD
Pages 1477-1483 | Published online: 28 Sep 2009

Bibliography

  • Diabetes fact sheet no. 312. Geneva, Switzerland:World Health Organization, 2008. http://wwwwhoint/mediacentre/factsheets/fs312/en/indexhtml: [Last accessed 17 March 2009]
  • Grundy SM, Brewer HB Jr, Cleeman JI, et al. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004;109(3):433-8
  • Newell-Price J, Bertagna X, Grossman AB, Nieman LK. Cushing's syndrome. Lancet 2006;367(9522):1605-17
  • Rask E, Olsson T, Soderberg S, et al. Tissue-specific dysregulation of cortisol metabolism in human obesity. J Clin Endocrinol Metab 2001;86(3):1418-21
  • Bjorntorp P, Rosmond R. Obesity and cortisol. Nutrition 2000;16(10):924-36
  • Fraser R, Ingram MC, Anderson NH, et al. Cortisol effects on body mass, blood pressure, and cholesterol in the general population. Hypertension 1999;33(6):1364-8
  • Atanasov AG, Odermatt A. Readjusting the glucocorticoid balance: an opportunity for modulators of 11beta-hydroxysteroid dehydrogenase type 1 activity? Endocr Metab Immune Disord Drug Targets 2007;7(2):125-40
  • Odermatt A, Atanasov AG. Mineralocorticoid receptors: emerging complexity and functional diversity. Steroids 2009;74(2):163-71
  • Goodwin JE, Zhang J, Geller DS. A critical role for vascular smooth muscle in acute glucocorticoid-induced hypertension. J Am Soc Nephrol 2008;19(7):1291-9
  • Wyrwoll CS, Seckl JR, Holmes MC. Altered placental function of 11beta-hydroxysteroid dehydrogenase 2 knockout mice. Endocrinology 2009;150(3):1287-93
  • Seckl JR, Holmes MC. Mechanisms of disease: glucocorticoids, their placental metabolism and fetal ‘programming’ of adult pathophysiology. Nat Clin Pract 2007;3(6):479-88
  • Seckl JR, Walker BR. 11beta-hydroxysteroid dehydrogenase type 1 as a modulator of glucocorticoid action: from metabolism to memory. Trends Endocrinol Metab 2004;15(9):418-24
  • Tomlinson JW, Walker EA, Bujalska IJ, et al. 11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr Rev 2004;25(5):831-66
  • Stewart PM, Boulton A, Kumar S, et al. Cortisol metabolism in human obesity: impaired cortisone–>cortisol conversion in subjects with central adiposity. J Clin Endocrinol Metab 1999;84(3):1022-7
  • Wake DJ, Rask E, Livingstone DE, et al. Local and systemic impact of transcriptional up-regulation of 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue in human obesity. J Clin Endocrinol Metab 2003;88(8):3983-8
  • Kannisto K, Pietilainen KH, Ehrenborg E, et al. Overexpression of 11{beta}-hydroxysteroid dehydrogenase-1 in adipose tissue is associated with acquired obesity and features of insulin resistance: studies in young adult monozygotic twins. J Clin Endocrinol Metab 2004;89(9):4414-21
  • Lindsay RS, Wake DJ, Nair S, et al. Subcutaneous adipose 11 beta-hydroxysteroid dehydrogenase type 1 activity and messenger ribonucleic acid levels are associated with adiposity and insulinemia in Pima Indians and Caucasians. J Clin Endocrinol Metab 2003;88(6):2738-44
  • Paulmyer-Lacroix O, Boullu S, Oliver C, et al. Expression of the mRNA coding for 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue from obese patients: an in situ hybridization study. J Clin Endocrinol Metab 2002;87(6):2701-5
  • Rask E, Walker BR, Soderberg S, et al. Tissue-specific changes in peripheral cortisol metabolism in obese women: increased adipose 11beta-hydroxysteroid dehydrogenase type 1 activity. J Clin Endocrinol Metab 2002;87(7):3330-6
  • Valsamakis G, Anwar A, Tomlinson JW, et al. 11beta-hydroxysteroid dehydrogenase type 1 activity in lean and obese males with type 2 diabetes mellitus. J Clin Endocrinol Metab 2004;89(9):4755-61
  • Desbriere R, Vuaroqueaux V, Achard V, et al. 11beta-hydroxysteroid dehydrogenase type 1 mRNA is increased in both visceral and subcutaneous adipose tissue of obese patients. Obesity (Silver Spring) 2006;14(5):794-8
  • Paterson JM, Seckl JR, Mullins JJ. Genetic manipulation of 11beta-hydroxysteroid dehydrogenases in mice. Am J Physiol Regul Integr Comp Physiol 2005;289(3):R642-52
  • Masuzaki H, Paterson J, Shinyama H, et al. A transgenic model of visceral obesity and the metabolic syndrome. Science 2001;294(5549):2166-70
  • Masuzaki H, Yamamoto H, Kenyon CJ, et al. Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. J Clin Invest 2003;112(1):83-90
  • Kotelevtsev Y, Holmes MC, Burchell A, et al. 11beta-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc Natl Acad Sci USA 1997;94(26):14924-9
  • Morton NM, Holmes MC, Fievet C, et al. Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11beta-hydroxysteroid dehydrogenase type 1 null mice. J Biol Chem 2001;276(44):41293-300
  • Morton NM, Paterson JM, Masuzaki H, et al. Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11 beta-hydroxysteroid dehydrogenase type 1-deficient mice. Diabetes 2004;53(4):931-8
  • Alberts P, Engblom L, Edling N, et al. Selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice. Diabetologia 2002;45(11):1528-32
  • Alberts P, Nilsson C, Selen G, et al. Selective inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains. Endocrinology 2003;144(11):4755-62
  • Alberts P, Ronquist-Nii Y, Larsson C, et al. Effect of high-fat diet on KKAy and ob/ob mouse liver and adipose tissue corticosterone and 11-dehydrocorticosterone concentrations. Horm Metab Res 2005;37(7):402-7
  • Barf T, Vallgarda J, Emond R, et al. Arylsulfonamidothiazoles as a new class of potential antidiabetic drugs. Discovery of potent and selective inhibitors of the 11beta-hydroxysteroid dehydrogenase type 1. J Med Chem 2002;45(18):3813-5
  • Sundbom M, Kaiser C, Bjorkstrand E, et al. Inhibition of 11betaHSD1 with the S-phenylethylaminothiazolone BVT116429 increases adiponectin concentrations and improves glucose homeostasis in diabetic KKAy mice. BMC Pharmacol 2008;8:3
  • Hermanowski-Vosatka A, Balkovec JM, Cheng K, et al. 11beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. J Exp Med 2005;202(4):517-27
  • Wang SJ, Birtles S, de Schoolmeester J, et al. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 reduces food intake and weight gain but maintains energy expenditure in diet-induced obese mice. Diabetologia 2006;49(6):1333-7
  • Veniant MM, Hale C, Komorowski R, et al. Time of the day for 11beta-HSD1 inhibition plays a role in improving glucose homeostasis in DIO mice. Diabetes Obesity Metab 2009;11(2):109-17
  • Moreno-Diaz H, Villalobos-Molina R, Ortiz-Andrade R, et al. Antidiabetic activity of N-(6-substituted-1,3-benzothiazol-2-yl)benzenesulfonamides. Bioorg Med Chem Lett 2008;18(9):2871-7
  • Fotsch C, Askew BC, Chen JJ. 11beta-Hydroxysteroid dehydrogenase-1 as a therapeutic target for metabolic diseases. Exp Opin Ther Patents 2005;15:289-303
  • Webster SP, Palin TD. 11beta-Hydroxysteroid dehydrogenase type 1 inhibitors as therapeutic agents. Exp Opin Ther Patents 2007;17(12):1407-22
  • Boyle C, Kowalski T. 11beta-HSD1 inhibitors: a review of recent patents. Exp Opin Ther Patents 2009(In Press)
  • Huang W, Naughton MA, Yang H, et al. Design, synthesis, and structure-activity relationships of unsubstituted piperazinone-based transition state factor Xa inhibitors. Bioorg Med Chem Lett 2003;13(4):723-8
  • COR Therapeutics. Selective factor Xa inhibitors. AO9846591; 1998
  • COR Therapeutics. Selective factor Xa inhibitors. WO9846628; 1998
  • COR Therapeutics. Selective factor Xa inhibitors. US6211183; 2001
  • COR Therapeutics. Selective factor Xa inhibitors. US6133256; 2001
  • Glaxo Group Ltd. 1, 4!-Diazepane-1-carboxylic acid derivatives process for their preparation and their use as tachykinin antagonists. WO2002081457; 2002
  • Asubio Pharma Co Ltd. 7-Membered ring compound, process for producing the same, and medicinal use thereof. WO2006059801; 2006
  • Persson B, Kallberg Y, Bray JE, et al. The SDR (short-chain dehydrogenase/reductase and related enzymes) nomenclature initiative. Chem Biol Interact 2008;178(1-3):94-8
  • Odermatt A, Arnold P, Stauffer A, et al. The N-terminal anchor sequences of 11beta-hydroxysteroid dehydrogenases determine their orientation in the endoplasmic reticulum membrane. J Biol Chem 1999;274(40):28762-70
  • Schuster D, Maurer EM, Laggner C, et al. The discovery of new 11beta-hydroxysteroid dehydrogenase type 1 inhibitors by common feature pharmacophore modeling and virtual screening. J Med Chem 2006;49(12):3454-66
  • Schuster D, Nashev LG, Kirchmair J, et al. Discovery of nonsteroidal 17beta-hydroxysteroid dehydrogenase 1 inhibitors by pharmacophore-based screening of virtual compound libraries. J Med Chem 2008;51(14):4188-99
  • Hoffmann F, Maser E. Carbonyl reductases and pluripotent hydroxysteroid dehydrogenases of the short-chain dehydrogenase/reductase superfamily. Drug Metab Rev 2007;39(1):87-144
  • Nashev LG, Chandsawangbhuwana C, Balazs Z, et al. Hexose-6-phosphate dehydrogenase modulates 11beta-hydroxysteroid dehydrogenase type 1-dependent metabolism of 7-keto- and 7beta-hydroxy-neurosteroids. PLoS ONE 2007;2:e561
  • Muller C, Pompon D, Urban P, Morfin R. Inter-conversion of 7alpha- and 7beta-hydroxy-dehydroepiandrosterone by the human 11beta-hydroxysteroid dehydrogenase type 1. J Steroid Biochem Mol Biol 2006;99(4-5):215-22
  • Hennebert O, Le Mee S, Pernelle C, Morfin R. 5Alpha-androstane-3beta, 7alpha,17beta-triol and 5alpha-androstane-3beta,7beta, 17beta-triol as substrates for the human 11beta-hydroxysteroid dehydrogenase type 1. Steroids 2007;72(13):855-64
  • Hult M, Elleby B, Shafqat N, et al. Human and rodent type 1 11beta-hydroxysteroid dehydrogenases are 7beta-hydroxycholesterol dehydrogenases involved in oxysterol metabolism. Cell Mol Life Sci 2004;61(7-8):992-9
  • Schweizer RA, Zurcher M, Balazs Z, et al. Rapid hepatic metabolism of 7-ketocholesterol by 11beta-hydroxysteroid dehydrogenase type 1: species-specific differences between the rat, human, and hamster enzyme. J Biol Chem 2004;279(18):18415-24
  • Bannenberg G, Martin HJ, Belai I, Maser E. 11beta-Hydroxysteroid dehydrogenase type 1: tissue-specific expression and reductive metabolism of some anti-insect agent azole analogues of metyrapone. Chem Biol Interact 2003;143-144:449-57
  • Maser E, Friebertshauser J, Volker B. Purification, characterization and NNK carbonyl reductase activities of 11beta-hydroxysteroid dehydrogenase type 1 from human liver: enzyme cooperativity and significance in the detoxification of a tobacco-derived carcinogen. Chem Biol Interact 2003;143-144:435-48
  • Kenneke JF, Mazur CS, Ritger SE, Sack TJ. Mechanistic investigation of the noncytochrome P450-mediated metabolism of triadimefon to triadimenol in hepatic microsomes. Chem Res Toxicol 2008;21(10):1997-2004
  • Arampatzis S, Kadereit B, Schuster D, et al. Comparative enzymology of 11beta-hydroxysteroid dehydrogenase type 1 from six species. J Mol Endocrinol 2005;35(1):89-101
  • Hult M, Shafqat N, Elleby B, et al. Active site variability of type 1 11beta-hydroxysteroid dehydrogenase revealed by selective inhibitors and cross-species comparisons. Mol Cell Endocrinol 2006;248(1-2):26-33
  • Chapman KE, Coutinho AE, Gray M, et al. The role and regulation of 11beta-hydroxysteroid dehydrogenase type 1 in the inflammatory response. Mol Cell Endocrinol 2009;301(1-2):123-31

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.